Pharmaceuticals, Biotechnology and Life Sciences
Abivax said on Tuesday it would receive €8.4 million from “Projets de R&D Structurants Pour la Compétitivité” (PSPC) of the “Invest in the Future Program” (PIA).
European Commission has granted marketing authorisation for Novo Nordisk’s Fiasp for the treatment of diabetes in adults.
Futura Medical (Futura) has signed a licensing agreement with the UK subsidiary of STADA Arzneimittel AG (STADA), for the commercialisation of TPR100, its pain relief gel.
A UK-based maker of hair and skin care products InnovaDerma has been engaged in looking for an independent non-executive Director of the company, as Garry Lemair has decided to step down the board immediately, the company said on Tuesday.
The European Patent Office has decided to grant Active Biotech’s patent application covering tasquinimod for use in the treatment of…
On 28 October 2016, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014…
An IT provider for healthcare market Instem, has appointed MaryBeth Thompson as Chief Operating Officer of the Group. Thompson has not been appointed to the company’s main Board, and she will report to Phil Reason, CEO.
Oxular Limited, a retinal therapeutics company, has promoted David Fellows, previously Non-Executive Director, as the Company’s Chairman of the Board. Fellows will replace Dr. Nigel Pitchford, who will continue on Oxular’s Board as a Director.
Bristol-Myers Squibb (BMS) has reached a payment milestone in connection with the licensing deal with Innate Pharma for lirilumab in combination with Opdivo. BMS has paied Innate $15 million.
Sweden-based pharmaceutical company Orphan Biovitrum AB (Sobi) has began looking for the new Chief Executive Officer (CEO), presumably a residence of Europe. The company said on Monday that its current boss, Geoffrey McDonough will leave the company in six months, on July 1, 2017.